论文部分内容阅读
目的：观察胸腺肽α1（Tα1）对化疗期间恶性肿瘤患者的免疫功能影响。方法：20例晚期恶性肿瘤患者随机分成A，B两组。A组给予单一化疗；B组在化疗同时给予Tα11．6mg／次，sc，2次／周，连用2个月。两组病例在治疗前后分别用流式细胞仪测定外周血T细胞亚群（CD3，CD4，CD8及CD4／CD8）和NK细胞活性。结果：B组的CD4，CD4／CD8和NK细胞活性治疗后明显高于治疗前，有统计学意义（P＜0．05）。治疗后A，B两组相比，B组的NK细胞活性明显高于A组，有统计学意义（P＜0．05）。结论：Tα1能明显提高肿瘤患者的免疫功能，特别对提高NK细胞活性尤为明显，并且没有发现明显的毒副作用，是一种低毒高效的生物反应调节剂。
Objective: To observe the effect of thymosin α1 (Tα1) on the immune function of patients with malignant tumor during chemotherapy. Methods: Twenty patients with advanced malignant tumors were randomly divided into A and B groups. A group was given a single chemotherapy; group B was given Tα11.6 mg/a at the time of chemotherapy, sc, 2 times/week, used for 2 months. Flow cytometry was used to measure peripheral blood T-cell subsets (CD3, CD4, CD8, and CD4/CD8) and NK cell activity before and after treatment in both groups. Results: The activity of CD4, CD4/CD8 and NK cells in group B was significantly higher than that before treatment (P<0.05). After treatment, the NK cell activity in group B was significantly higher than that in group A, which was statistically significant (P<0.05). Conclusion: Tα1 can significantly improve the immune function of cancer patients, especially for improving the activity of NK cells, and no obvious toxic side effects are found. It is a low toxicity and high efficiency biological response modifier.